Core Laboratories (CLB) Cash & Equivalents (2022 - 2026)

Core Laboratories' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $22.7 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 27.1% year-over-year to $22.7 million; the TTM figure through Jun 2026 stood at $22.7 million (down 27.1% YoY), while the FY2025 annual figure was $22.7 million, up 18.5% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $22.7 million, roughly flat from $22.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $31.2 million in Q2 2025, with the low at $14.9 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $21.8 million (2024), against an average of $21.0 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 32.47% in 2024, then soared 76.25% in 2025.
• Core Laboratories' Cash & Equivalents stood at $15.4 million in 2022, then retreated by 2.0% to $15.1 million in 2023, then climbed by 26.7% to $19.2 million in 2024, then advanced by 18.5% to $22.7 million in 2025, then advanced by 0.15% to $22.7 million in 2026.
• Business Quant data shows CLB's Cash & Equivalents at $22.7 million in Q2 2026, $22.8 million in Q1 2026, and $22.7 million in Q4 2025.